Teva Pharmaceutical Industries Limited

NYSE:TEVA

Drug Manufacturers - Specialty & Generic

Healthcare
$42.23 -3.35%

-$1.09 today

Market cap
$49.28B
Beta
0.85
P/E (TTM)
23.1
EPS (TTM)
$1.36
52W Low $14.99High $37.35

Volume 8.86M

Average 6.22M

TEVA Pre-Tax Margin

Income before tax as a percentage of revenue.

Teva Pharmaceutical Industries LimitedNYSE: TEVA

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to -11.0%

Pre-tax margin was -11.0% in Q2 FY2026, down 15.9 pp from a year earlier. On a trailing-twelve-month basis it was 4.2%, up 4.6 pp year over year. Over 3 fiscal years it widened by 28.2 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-11.0%-21.9 pp QoQ
Last fiscal yearDec 2025
7.2%+14.9 pp YoY
LTMJun 2026
4.2%+4.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-15.9 pp——
1 year+14.9 pp——
3 years+28.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
7.2%
Year-over-year change
+14.9pp

Pre-Tax Margin vs competitors

How TEVA compares with its peers on the latest reported figures

  • TEVA's LTM Jun 2026 pre-tax margin of 4.2% is the 4th highest of the 5 companies compared; the peer median is 7.2%.
  • Its year-over-year change of +4.6 pp is the 2nd highest of 5, against a peer median of -3.0 pp.
  • Over three fiscal years its change of +28.2 pp compares with a peer median of +3.8 pp.
TEVA Competitors Peer median
Pre-Tax Margin for TEVA and competitors
Company Period LTM level YoY 3-year change
RDYDr. Reddy's Laboratories LimitedLTM Sep 202610.6% -11.6 pp-8.2 pp
ALVOAlvotechLTM Mar 20267.8% -9.4 pp+687.7 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 20266.5% +3.3 pp+15.8 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20264.2% +4.6 pp+28.2 pp
VTRSViatris Inc.LTM Jun 2026-4.5% +22.1 pp-42.9 pp
Peer median (excluding TEVA) 7.2%-3.0 pp+3.8 pp

Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15.88B14.93B15.85B16.54B17.26B
Cost of Revenue8.28B7.95B8.2B8.48B8.32B
Gross Profit7.59B6.97B7.65B8.06B8.94B
Gross Margin47.8%46.7%48.2%48.7%51.8%
Research & Development1.09B838M953M1.06B1.01B
Selling, General & Admin3.53B3.45B3.5B3.7B3.97B
Operating Expenses5.88B9.17B7.21B8.37B6.78B
Depreciation & Amortization1.33B1.31B1.15B1.06B1B
EBITDA4.41B(925M)1.56B4.43B3.14B
EBITDA Margin27.8%-6.2%9.8%26.8%18.2%
Operating Income1.72B(2.2B)433M(303M)2.16B
Operating Margin10.8%-14.7%2.7%-1.8%12.5%
Interest Income0068M00
Interest Expense891M930M1.03B941M916M
Other Income / Expenses(1.05B)(945M)(1.06B)(980M)(919M)
Income Before Tax667M(3.14B)(622M)(1.28B)1.24B
Pre-Tax Margin4.2%-21.1%-3.9%-7.8%7.2%
Income Tax Expense211M(643M)(7M)676M(180M)
Net Income417M(2.45B)(559M)(1.64B)1.41B
Net Margin2.6%-16.4%-3.5%-9.9%8.2%
EPS (Basic)0.38(2.20)(0.50)(1.45)1.23
EPS (Diluted)0.38(2.20)(0.50)(1.45)1.20
Weighted Avg Shares1.1B1.11B1.12B1.13B1.15B
Weighted Avg Shares (Diluted)1.11B1.11B1.12B1.13B1.17B

Teva Pharmaceutical Industries Limited

NYSE:TEVA

Intrinsic Alpha fair value

Locked

Current Price

$42.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.